NCT01556594View on ClinicalTrials.gov

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Hypoglycemia
Interventions
DRUG

Nasal Glucagon 1 mg

DRUG

Nasal Glucagon 2 mg

DRUG

SC Glucagon

DRUG

Nasal Glucagon 3 mg

Trial Locations (1)

H3P 3P1

Algorithme Pharma, Montreal

Sponsors

Collaborators (1)

Locemia Solutions ULC
All Listed Sponsors
collaborator

Locemia Solutions ULC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT01556594 - Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia | Biotech Hunter | Biotech Hunter